Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF) on no Background Anti-fibrotic (Part 1) and Safety and Tolerability of BI 1015550 on Top of Nintedanib and Pirfenidone (Part 2)

Trial Profile

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF) on no Background Anti-fibrotic (Part 1) and Safety and Tolerability of BI 1015550 on Top of Nintedanib and Pirfenidone (Part 2)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 May 2018

At a glance

  • Drugs BI 1015550 (Primary) ; Nintedanib; Pirfenidone
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 20 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 05 Mar 2018 Planned initiation date changed from 21 Feb 2018 to 9 Mar 2018.
    • 08 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top